Ge Long Hui A P P·2025-08-25 07:42Core Viewpoint - The report from Zhongyin Securities indicates that Huadong Medicine's net profit attributable to shareholders for the first half of the year reached 1.815 billion yuan, representing a year-on-year growth of 7.01% [1] Business Segments Summary - The industrial segment of the company continues to grow rapidly, with its core subsidiary, China Medical Huadong, achieving revenue of 7.317 billion yuan (including CSO business), a year-on-year increase of 9.24%, and a net profit of 1.580 billion yuan, up 14.09% year-on-year [1] - The commercial segment reported revenue of 13.947 billion yuan in the first half, reflecting a year-on-year growth of 2.91%, with a net profit of 226 million yuan, an increase of 3.67% year-on-year [1] - The medical beauty segment faced external pressures from global macroeconomic fluctuations and market demand adjustments, resulting in a revenue of 1.112 billion yuan, showing a decline year-on-year [1] - The industrial microbiology segment achieved a total revenue of 368 million yuan, marking a year-on-year growth of 29% [1] Future Outlook - The company is optimistic about the future development prospects of its industrial segment as innovative products gradually enter the harvest period [1] - The commercialization team is continuously expanding and improving the commercial network to ensure sustained growth of the company's innovative products [1]